Company profile
Seagen, a wholly owned subsidiary of Pfizer
Privately held: no public share price · United States
Assets
(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | PD-L1Antibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 3 | Integrin beta-6 (ITGB6)Antibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 1 | CEACAM5Antibody–drug conjugate | Non-Small Cell Lung Cancer |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.